The art and science of running a successful pharmaceutical company.
February 3, 2010
By:George Koroneos, Online Content & News Editor
Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.
 |
February 1, 2010
By:John Evans, Winston Chen
Bad data ? and a lack of good data management practices ? can cost your business millions of dollars every year. You have to treat your data like every other valuable asset in your business: You must protect it, nurture it and ensure that, like any asset, it?s in the best condition possible.
|
February 1, 2010
Abbott Laboratories tapped Kalido?s model-driven data warehousing infrastructure to revamp?and revive?an overworked BI system. Executives can view accurate, timely data in each of several different contexts?historical, current, or future. The new system also gives Abbott?s sales and marketing executives better insight into how efficiently the company is allocating its sales and marketing investments, particularly in emerging markets.
|
 | January 27, 2010
By:William Looney
In a disruptive era of change, old-fashioned intuition still counts.
|
 | January 20, 2010
By:Walter Armstrong
Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?
|
January 20, 2010
By:George Koroneos, Online Content & News Editor
GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.
|
 | January 13, 2010
By:George Koroneos
A new pharma consortium focuses on securing the supply chain upstream. Pharm Exec interviews Rx360 to learn more.
|
 | January 1, 2010
By:Mason Tenaglia
Designing and deploying company copay offset programs without devaluing the brand.
|
December 16, 2009
By:George Koroneos
Transparency can be a double-edged sword - especially if you are a doctor receiving money to speak on behalf of a drug company. Sure the pay day is nice, but does the public outing open you up to scrutiny?
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA